SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Rubicon Research’s arm enters into definitive agreement with GEn1E Lifesciences Inc

23 Oct 2025 Evaluate

Rubicon Research’s subsidiary -- Advagen Holdings Inc. (Advagen) has entered into a definitive agreement with GEn1E Lifesciences Inc. (Gen1E), to acquire Series Prime Preferred Stock in tranches, for a total consideration of up to $3 million. Series Prime Preferred Stock, convertible into around 2.2% of Gen1E’s common stock ownership subject to achievement of all milestones.

Gen1E is a pharmaceutical company with a pipeline of product candidates under development. GEn1E is based in Palo Alto, California, with a laboratory in Mountain View, California, USA.

Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality products and drug-device combination products targeting regulated markets and in particular the United States.

Rubicon Research Share Price

919.55 22.50 (2.51%)
20-Apr-2026 14:36 View Price Chart
Peers

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×